DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Metastatic Colorectal Cancer pipeline landscape. It covers the Metastatic Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Colorectal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Metastatic Colorectal Cancer pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight’s comprehensive Metastatic Colorectal Cancer Pipeline Report to explore emerging therapies, key Metastatic Colorectal Cancer Companies, and future Metastatic Colorectal Cancer treatment landscapes @ Metastatic Colorectal Cancer Pipeline Outlook Report
Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report
- In February 2025:- Buzzard Pharmaceuticals:- This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated. Patients must have been treated with available approved treatments already. In this study the investoigators are testing a new type of immunotherapy aclled isunakinra to be added to already approved immunotherapy (PD-1/PD-L1 inhibitor) in an attempt to get this otherwise effective treatment to work on this treatment resistant type of tumor.
- In February 2025:- AbbVie:- Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused ABBV-400 to trifluridine and tipiracil (LONSURF) oral tablets plus IV infused bevacizumab in adult participants with c-Met over-expressed refractory metastatic colorectal cancer (mCRC).
- In January 2025:- Cardiff Oncology:- The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irinotecan, fluorouracil [5-FU], and leucovorin (FOLFIRI) and bevacizumab for treatment of confirmed metastatic and/or unresectable colorectal cancer (CRC) in participants with a kirsten rat sarcoma virus gene (KRAS) or neuroblastoma-RAS (NRAS) mutation who have progressed on an oxaliplatin/fluoropyrimidinebased regimen in the first-line setting.
- In January 2025:- Menarini Group:- This Phase Ib/II study will investigate the anti-tumour activity and safety of daily oral doses MEN1611 in combination with cetuximab in female and male patients affected by PIK3CA mutated, N-K-RAS wild-type and BRAF wild-type metastatic colorectal cancer.
- In January 2025:- Amgen:- The aim of this study is to compare progression free survival (PFS) in treatment-naïve Participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
- DelveInsight’s Metastatic Colorectal Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Metastatic Colorectal Cancer treatment.
- The leading Metastatic Colorectal Cancer Companies such as Amgen, Pfizer, Nurix Therapeutics Inc, Sumitomo Dainippon Pharma Oncology, Novocure, Processa Pharmaceuticals, Daiichi Sankyo, Qilu Pharmaceutical Co., Ltd., Binhui Biopharmaceutical, Parasol Biotech, Syndax Pharmaceuticals, Innovative Cellular Therapeutics, Immvira Pharma, ISA Pharmaceuticals, Jiangsu Hengrui Medicine, Peptomyc, Xbrane, TransCode Therapeutics, Servier, Jemincare, XBiotech and others.
- Promising Metastatic Colorectal Cancer Therapies such as Regorafenib, Cyclophosphamide, Capecitabine, NV1020, MRTX849, Pembrolizumab, Cetuximab, erlotinib, FOLFOX, and others.
Discover how the Metastatic Colorectal Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Metastatic Colorectal Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Metastatic Colorectal Cancer Clinical Trials and Studies
Metastatic Colorectal Cancer Emerging Drugs Profile
- Lumakras (sotorasib): Amgen
Lumakras (sotorasib) is a highly selective inhibitor of KRAS G12C that potentially suppresses the rapid proliferation of cancer cells. Sotorasib forms an irreversible, covalent bond with the cysteine residue of KRAS G12C, holding the protein in its inactive form that blocks the oncogenic signaling. This results in apoptosis only in KRAS G12C tumor cell. It is being investigated as a treatment for a variety of solid tumors, including NSCLC, colorectal cancer and other solid tumor cancers. Currently, the drug is in the Phase III stage of its development for the treatment of Metastatic Colorectal Cancer.
- Axitinib: Pfizer
Axitinib is an oral therapy that is designed to inhibit tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors 1, 2 and 3; these receptors can influence tumor growth, vascular angiogenesis and progression of cancer. In the U.S., INLYTA is approved for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. Currently, the drug is in the Phase II stage of its development for the treatment of Metastatic Colorectal Cancer.
- NX 1607: Nurix Therapeutics Inc
NX-1607 is an orally bioavailable inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B) for immuno-oncology indications, including a range of solid tumor types. NX-1607 acts on T cells, NK cells, and dendritic cells to enhance anti-tumor immunity, and has demonstrated single-agent anti-tumor activity in multiple tumor models. Nurix is evaluating NX-1607 in an ongoing, Phase I dose escalation and expansion trial in adults with a variety of oncology indications at multiple clinical sites. Currently, the drug is in the Phase I stage of its development for the treatment of Metastatic Colorectal Cancer.
- TP-1454: Sumitomo Dainippon Pharma Oncology
TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator that is currently being evaluated in a Phase I/I b study in patients with advanced metastatic or progressive solid tumors. TP-1454 is the first PKM2 activator to be evaluated in cancer patients. Pyruvate kinase is the enzyme responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment. Currently, the drug is in the Phase I stage of its development for the treatment of Metastatic Colorectal Cancer.
The Metastatic Colorectal Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Colorectal Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Colorectal Cancer Treatment.
- Metastatic Colorectal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Metastatic Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Colorectal Cancer market.
Get a detailed analysis of the latest innovations in the Metastatic Colorectal Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Metastatic Colorectal Cancer Unmet Needs
Metastatic Colorectal Cancer Companies
Amgen, Pfizer, Nurix Therapeutics Inc, Sumitomo Dainippon Pharma Oncology, Novocure, Processa Pharmaceuticals, Daiichi Sankyo, Qilu Pharmaceutical Co., Ltd., Binhui Biopharmaceutical, Parasol Biotech, Syndax Pharmaceuticals, Innovative Cellular Therapeutics, Immvira Pharma, ISA Pharmaceuticals, Jiangsu Hengrui Medicine, Peptomyc, Xbrane, TransCode Therapeutics, Servier, Jemincare, XBiotech and others.
Metastatic Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
Metastatic Colorectal Cancer Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Download DelveInsight’s latest report to gain strategic insights into upcoming Metastatic Colorectal Cancer Therapies and key Metastatic Colorectal Cancer Developments @ Metastatic Colorectal Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the Metastatic Colorectal Cancer Pipeline Report
- Coverage- Global
- Metastatic Colorectal Cancer Companies- Amgen, Pfizer, Nurix Therapeutics Inc, Sumitomo Dainippon Pharma Oncology, Novocure, Processa Pharmaceuticals, Daiichi Sankyo, Qilu Pharmaceutical Co., Ltd., Binhui Biopharmaceutical, Parasol Biotech, Syndax Pharmaceuticals, Innovative Cellular Therapeutics, Immvira Pharma, ISA Pharmaceuticals, Jiangsu Hengrui Medicine, Peptomyc, Xbrane, TransCode Therapeutics, Servier, Jemincare, XBiotech and others.
- Metastatic Colorectal Cancer Therapies- Regorafenib, Cyclophosphamide, Capecitabine, NV1020, MRTX849, Pembrolizumab, Cetuximab, erlotinib, FOLFOX, and others.
- Metastatic Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Metastatic Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Metastatic Colorectal Cancer drug development? Find out in DelveInsight’s exclusive Metastatic Colorectal Cancer Pipeline Report—access it now! @ Metastatic Colorectal Cancer Emerging Drugs and Major Companies
Table of Content
- Introduction
- Executive Summary
- Metastatic colorectal cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Metastatic colorectal cancer – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Metastatic colorectal cancer Collaboration Deals
- Late Stage Products (Phase III)
- Lumakras (sotorasib): Amgen
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Axitinib: Pfizer
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- NX 1607: Nurix Therapeutics Inc
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Metastatic colorectal cancer Key Companies
- Metastatic colorectal cancer Key Products
- Metastatic colorectal cancer- Unmet Needs
- Metastatic colorectal cancer- Market Drivers and Barriers
- Metastatic colorectal cancer- Future Perspectives and Conclusion
- Metastatic Colorectal Cancer Analyst Views
- Metastatic Colorectal Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/oral-electrolyte-solutions-market